Advertisement

Current Oncology Reports

, 20:103 | Cite as

Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

  • Ciara L. FreemanEmail author
  • Laurie Sehn
Lymphomas (MR Smith, Section Editor)
  • 171 Downloads
Part of the following topical collections:
  1. Topical Collection on Lymphomas

Abstract

Purpose of Review

Since its initial approval in 1997, rituximab has revolutionized the treatment of CD20-positive lymphoproliferative disorders. Now, over two decades later, second-generation molecules are emerging that may have key biological advantages compared to rituximab, as well as biosimilars that may be more cost-effective. Clinicians, health policy makers, and payers will now need to critically appraise the available evidence for these competitors and decide which anti-CD20 to use.

Recent Findings

Evidence has emerged directly comparing rituximab IV to a subcutaneous preparation, and head-to-head comparisons of rituximab versus next-generation anti-CD20 monoclonal antibodies have also been published. Trials comparing rituximab with newly developed biosimilars have also allowed for registration of these agents.

Summary

In this review, we will present an overview of anti-CD20 monoclonal antibody development, discuss the mechanistic and clinical evidence for rituximab, as well as the novel compounds, and provide commentary on the possible advantages and limitations of these agents.

Keywords

Lymphoma CLL CD20 Monoclonal antibodies Rituximab Immunotherapy Biosimilar 

Notes

Compliance with Ethical Standards

Conflict of Interest

Ciara L. Freeman has received research funding through grants from Roche and Genentech, has served on advisory boards for AbbVie and Celgene, and has received honoraria for service as a consultant from Seattle Genetics.

Laurie Sehn has received research funding through grants from Roche and Genentech and has received honoraria from Roche, Genentech, Seattle Genetics, AbbVie, Celgene, Amgen, Gilead, TG Therapeutics, Pfizer, Karyopharm, Apobiologix, Lundbeck, and Janssen for service as a consultant.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Nadler LM, Ritz J, Hardy R, Pesando JM, Schlossman SF, Stashenko P. A unique cell surface antigen identifying lymphoid malignancies of B cell origin. J Clin Invest. 1981;67(1):134–40.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Stashenko P, et al. Characterization of a human B lymphocyte-specific antigen. J Immunol. 1980;125(4):1678–85.PubMedGoogle Scholar
  3. 3.
    Pierpont TM, Limper CB, Richards KL. Past, present, and future of rituximab-the world’s first oncology monoclonal antibody therapy. Front Oncol. 2018;8:163.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Beers SA, Chan CHT, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol. 2010;47(2):107–14.PubMedGoogle Scholar
  5. 5.
    Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256(5517):495–7.Google Scholar
  6. 6.
    Nadler LM, et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res. 1980;40(9):3147–54.PubMedGoogle Scholar
  7. 7.
    Reff ME. The discovery of rituxan. In: The process of new drug discovery and development. 2nd ed. New York: Informa Healthcare; 2006, ed. C.G.O.D. Smith, J. 2006, New York: Informa Healthcare.Google Scholar
  8. 8.
    Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984;81(21):6851–5.PubMedPubMedCentralGoogle Scholar
  9. 9.
    Pyzik M, et al. FcRn: The architect behind the immune and non-immune functions of IgG and albumin. J Immunol (Baltimore, Md. : 1950). 2015;194(10):4595–603.Google Scholar
  10. 10.
    •• Salles G, et al. Rituximab in b-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–73. Comprehensive review of rituximab across all malignant indications written by those involved in the pivotal trials and with extensive experience with this agent. PubMedPubMedCentralGoogle Scholar
  11. 11.
    Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–73.PubMedGoogle Scholar
  12. 12.
    • Davies A, et al. Subcutaneous rituximab for the treatment of b-cell hematologic malignancies: a review of the scientific rationale and clinical development. Adv Ther. 2017;34(10):2210–31. Overview of the development of the subcutaneous product. PubMedPubMedCentralGoogle Scholar
  13. 13.
    Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br J Cancer. 2013;109(6):1556–61.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Dakhil S, Hermann R, Schreeder MT, Gregory SA, Monte M, Windsor KS, et al. Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma. Leukemia & Lymphoma. 2014;55(10):2335–40.Google Scholar
  15. 15.
    Salar A, et al. Comparison of subcutaneous versus intravenous administration of rituximab as maintenance treatment for follicular lymphoma: results from a two-stage. J Clin Oncol: Phase IB Study; 2014.Google Scholar
  16. 16.
    Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, et al. Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol. 2015;80(5):1001–9.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Davies A, Merli F, Mihaljević B, Mercadal S, Siritanaratkul N, Solal-Céligny P, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–82.PubMedGoogle Scholar
  18. 18.
    Lugtenburg P, Avivi I, Berenschot H, Ilhan O, Marolleau JP, Nagler A, et al. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study. Haematologica. 2017;102(11):1913–22.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Assouline S, Buccheri V, Delmer A, Gaidano G, Trneny M, Berthillon N, et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial. Lancet Haematol. 2016;3(3):e128–38.PubMedGoogle Scholar
  20. 20.
    Panizo C, et al. Safety of subcutaneous administration of rituximab during the first-line treatment of patients with non-Hodgkin lymphoma: the MabRella study. Blood. 2016;128(22):2971.Google Scholar
  21. 21.
    Rummel M, et al. Prefmab: final analysis of patient preference for subcutaneous versus intravenous rituximab in previously untreated CD20+ diffuse large B-cell lymphoma and follicular lymphoma. Blood. 2015;126(23):3972.Google Scholar
  22. 22.
    Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459–68.PubMedGoogle Scholar
  23. 23.
    Ponzetti C, et al. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin’s lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey. Clinicoecon Outcomes Res. 2016;8:227–33.PubMedPubMedCentralGoogle Scholar
  24. 24.
    De Cock E, et al. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Fargier E, Ranchon F, Huot L, Guerre P, Safar V, Dony A, et al. SMABcare study: subcutaneous monoclonal antibody in cancer care: cost-consequence analysis of subcutaneous rituximab in patients with follicular lymphoma. Ann Hematol. 2018;97(1):123–31.PubMedGoogle Scholar
  26. 26.
    Wolfromm A, et al. home administration of subcutaneous rituximab is safe and associated with significant cost saving: a single center experience. Blood. 2017;130(Suppl 1):4676.Google Scholar
  27. 27.
    Cragg MS, et al. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140–74.PubMedGoogle Scholar
  28. 28.
    Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30(1 Suppl 2):3–8.PubMedGoogle Scholar
  29. 29.
    Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol. 2007;44(16):3823–37.PubMedGoogle Scholar
  30. 30.
    Chan HT, et al. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res. 2003;63(17):5480–9.PubMedGoogle Scholar
  31. 31.
    Cragg MS, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood. 2003;101(3):1045–52.PubMedGoogle Scholar
  32. 32.
    Teeling JL, et al. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. 2004;104(6):1793–800.PubMedGoogle Scholar
  33. 33.
    Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103(7):2738–43.PubMedGoogle Scholar
  34. 34.
    Alduaij W, Ivanov A, Honeychurch J, Cheadle EJ, Potluri S, Lim SH, et al. Novel type II anti-CD20 monoclonal antibody (GA101) evokes homotypic adhesion and actin-dependent, lysosome-mediated cell death in B-cell malignancies. Blood. 2011;117(17):4519–29.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Ivanov A, et al. Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest. 2009;119(8):2143–59.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Golay J, et al. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood. 2000;95(12):3900–8.PubMedGoogle Scholar
  37. 37.
    Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, et al. Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol Cancer Ther. 2013;12(10):2031–42.PubMedGoogle Scholar
  38. 38.
    Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99(3):1038–43.PubMedGoogle Scholar
  39. 39.
    Honeychurch J, Alduaij W, Azizyan M, Cheadle EJ, Pelicano H, Ivanov A, et al. Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012;119(15):3523–33.PubMedPubMedCentralGoogle Scholar
  40. 40.
    Di Gaetano N, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171(3):1581–7.PubMedGoogle Scholar
  41. 41.
    Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H, Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 2005;24(55):8114–27.PubMedGoogle Scholar
  42. 42.
    Bologna L, Gotti E, Manganini M, Rambaldi A, Intermesoli T, Introna M, et al. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab. J Immunol. 2011;186(6):3762–9.PubMedGoogle Scholar
  43. 43.
    Golay J, da Roit F, Bologna L, Ferrara C, Leusen JH, Rambaldi A, et al. Glycoengineered CD20 antibody obinutuzumab activates neutrophils and mediates phagocytosis through CD16B more efficiently than rituximab. Blood. 2013;122(20):3482–91.PubMedGoogle Scholar
  44. 44.
    Mozessohn L, et al. Rituximab resistant follicular lymphoma: predictors of rituximab resistance, incidence of transformation and prognosis. Blood. 2011;118(21):4981.Google Scholar
  45. 45.
    Bonavida B. Postulated mechanisms of resistance of B-cell non-Hodgkin lymphoma to rituximab treatment regimens: strategies to overcome resistance. Semin Oncol. 2014;41(5):667–77.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182(1):29–45.PubMedGoogle Scholar
  47. 47.
    Rezvani AR, Maloney DG. Rituximab resistance. Best Pract Res Clin Haematol. 2011;24(2):203–16.PubMedPubMedCentralGoogle Scholar
  48. 48.
    • Cartron G, Watier H. Obinutuzumab: what is there to learn from clinical trials? Blood. 2017;130(5):581–9. Very clear and comprehensive evaluation of this agent. PubMedGoogle Scholar
  49. 49.
    Keating MJ, Dritselis A, Yasothan U, Kirkpatrick P. Ofatumumab. Nat Rev Drug Discov. 2010;9(2):101–2.PubMedGoogle Scholar
  50. 50.
    Teeling JL, Mackus WJM, Wiegman LJJM, van den Brakel JHN, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol. 2006;177(1):362–71.PubMedGoogle Scholar
  51. 51.
    Wierda WG, Kipps TJ, Mayer J, Stilgenbauer S, Williams CD, Hellmann A, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749–55.PubMedPubMedCentralGoogle Scholar
  52. 52.
    Montillo M, Byrd JC, Hillmen P, O’Brien S, Barrientos JC, Reddy NM, et al. Long-term efficacy and safety in the resonate study: IBRUTINIB in patients with previously treated chronic lymphocytic leukemia (CLL) with up to four years follow-up. Hematol Oncol. 2017;35(S2):235–6.Google Scholar
  53. 53.
    Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213–23.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, et al. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385(9980):1873–83.PubMedGoogle Scholar
  55. 55.
    van Oers MH, et al. Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study. Lancet Oncol. 2015;16(13):1370–9.PubMedGoogle Scholar
  56. 56.
    Reyes C, et al. Cost-effectiveness analysis of obinutuzumab versus ofatumumab for previously untreated chronic lymphocytic leukemia (CLL). Blood. 2014;124(21):1324.Google Scholar
  57. 57.
    Wu Y, Wang Y, Gu Y, Xia J, Kong X, Qian Q, et al. Safety and efficacy of ofatumumab in chronic lymphocytic leukemia: a systematic review and meta-analysis. Hematology. 2017;22(10):578–84.PubMedGoogle Scholar
  58. 58.
    Marshall MJE, Stopforth RJ, Cragg MS. Therapeutic antibodies: what have we learnt from targeting CD20 and where are we going? Front Immunol. 2017;8:1245.PubMedPubMedCentralGoogle Scholar
  59. 59.
    •• Sopp J, Cragg MS. Deleting malignant b cells with second-generation anti-cd20 antibodies. J Clin Oncol. 2018;36(22):2323–5. Brief and succint overview of the mechanism of action of rituximab compared to next generation antiCD20 Mabs. PubMedGoogle Scholar
  60. 60.
    Imhoff GWv, et al. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large b-cell lymphoma: the ORCHARRD study. J Clin Oncol. 2017;35(5):544–51.PubMedGoogle Scholar
  61. 61.
    Maloney DG, Fukuhara N., Ogura M, Larouche JF, Tournilhac O, Coleman M, Hong X, Fennessy Cota M, Woessner M, Tobinai K. A phase III study of ofatumumab vs rituximab in indolent B-cell non-Hodgkin lymphoma relapsed after rituximab-containing therapy (HOMER): results of the interim analysis in 21st Annual Congress of the European Hematology Association. 2016: Copenhagen, Denmar.Google Scholar
  62. 62.
    Mössner E, et al. Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity. Blood. 2010;115(22):4393–402.PubMedPubMedCentralGoogle Scholar
  63. 63.
    Niederfellner G, Lammens A, Mundigl O, Georges GJ, Schaefer W, Schwaiger M, et al. Epitope characterization and crystal structure of GA101 provide insights into the molecular basis for type I/II distinction of CD20 antibodies. Blood. 2011;118(2):358–67.PubMedGoogle Scholar
  64. 64.
    Konitzer JD, et al. Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro. PLoS One. 2015;10(12):e0145633.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Umana P, et al. GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. Blood. 2007;110(11):2348.Google Scholar
  66. 66.
    Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, et al. Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients. Blood. 2012;119(22):5126–32.PubMedGoogle Scholar
  67. 67.
    Salles GA, Morschhauser F, Solal-Céligny P, Thieblemont C, Lamy T, Tilly H, et al. Obinutuzumab (GA101) in patients with relapsed/refractory indolent non-Hodgkin lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2920–6.PubMedGoogle Scholar
  68. 68.
    Sehn LH, Assouline SE, Stewart DA, Mangel J, Gascoyne RD, Fine G, et al. A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2012;119(22):5118–25.PubMedGoogle Scholar
  69. 69.
    Sehn LH, Goy A, Offner FC, Martinelli G, Caballero MD, Gadeberg O, et al. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: Final analysis of the GAUSS study. J Clin Oncol. 2015;33(30):3467–74.PubMedPubMedCentralGoogle Scholar
  70. 70.
    Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101–10.PubMedGoogle Scholar
  71. 71.
    Goede V, Fischer K., Dyer MJS, Müller L, Smolej L, Di Bernardo MC, Knapp A, Nielsen T, Hallek M Overall survival benefit of obinutuzumab over rituximab when combined with chlorambucil in patients with chronic lymphocytic leukemia and comorbidities: final survival analysis of the CLL11 study. in European Hematology Association 2018. EHA Learning Center.Google Scholar
  72. 72.
    Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, et al. Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM study: influence of chemotherapy on efficacy and safety. J Clin Oncol. 2018;36(23):2395–404.PubMedGoogle Scholar
  73. 73.
    Marcus R, Davies A, Ando K, Klapper W, Opat S, Owen C, et al. Obinutuzumab for the first-line treatment of follicular lymphoma. N Engl J Med. 2017;377(14):1331–44.PubMedGoogle Scholar
  74. 74.
    Friedberg JW. Progress in advanced-stage follicular lymphoma. J Clin Oncol. 2018;36(23):2363–5.PubMedGoogle Scholar
  75. 75.
    Casasnovas R-O, et al. Obinutuzumab versus rituximab in combination with ACVBP-14 or CHOP-14 following a PET-driven strategy in Aa-IPI 1-3 DLBCL patients (< 60 years): third planned interim and final analyses of the Gained trial. Blood. 2017;130(Suppl 1):190.Google Scholar
  76. 76.
    Vitolo U, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. J Clin Oncol. 2017;0(0):JCO.2017.73.3402.Google Scholar
  77. 77.
    Cartron G, Hourcade-Potelleret F, Morschhauser F, Salles G, Wenger M, Truppel-Hartmann A, et al. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma. Haematologica. 2016;101(2):226–34.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Rafiq S, Butchar JP, Cheney C, Mo X, Trotta R, Caligiuri M, et al. Comparative assessment of clinically utilized CD20-directed antibodies in chronic lymphocytic leukemia cells reveals divergent NK cell, monocyte, and macrophage properties. J Immunol. 2013;190(6):2702–11.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Vitolo U, et al. Obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-cell lymphoma: final results from an open-label, randomized phase 3 study (GOYA). Blood. 2016;128(22):470.Google Scholar
  80. 80.
    Sacco JJ, Botten J, Macbeth F, Bagust A, Clark P. The average body surface area of adult cancer patients in the UK: a multicentre retrospective study. PLoS One. 2010;5(1):e8933.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Pott C, et al. Minimal residual disease in patients with follicular lymphoma treated with obinutuzumab or rituximab as first-line induction immunochemotherapy and maintenance in the phase 3 GALLIUM study. Blood. 2016;128(22):613.Google Scholar
  82. 82.
    Fischer K, al-Sawaf O, Fink AM, Dixon M, Bahlo J, Warburton S, et al. Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017;129:2702–5.PubMedPubMedCentralGoogle Scholar
  83. 83.
    Cramer P, von Tresckow J, Bahlo J, Robrecht S, Langerbeins P, al-Sawaf O, et al. Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(9):1215–28.PubMedGoogle Scholar
  84. 84.
    Launonen A, et al. Early disease progression predicts poorer survival in patients with follicular lymphoma (FL) in the GALLIUM study. Blood. 2017;130(Suppl 1):1490.Google Scholar
  85. 85.
    Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, et al. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study. J Clin Oncol. 2015;33(23):2516–22.PubMedPubMedCentralGoogle Scholar
  86. 86.
    Oestergaard MZ, et al. Superiority of obinutuzumab over rituximab in a new molecular follicular lymphoma-like subgroup of DLBCL: results from an exploratory analysis of the phase 3 GOYA trial. Blood. 2017;130(Suppl 1):1543.Google Scholar
  87. 87.
    de Romeuf C, Dutertre CA, le Garff-Tavernier M, Fournier N, Gaucher C, Glacet A, et al. Chronic lymphocytic leukaemia cells are efficiently killed by an anti-CD20 monoclonal antibody selected for improved engagement of FcgammaRIIIA/CD16. Br J Haematol. 2008;140(6):635–43.PubMedGoogle Scholar
  88. 88.
    Miller J, et al. Ublituximab (TGTX-1101), a novel anti-CD20 monoclonal antibody (mAb), demonstrates activity in rituximab-sensitive and rituximab–resistant B non-Hodgkin lymphoma (B-NHL) pre-clinical <em>in vitro</em> and <em>in vivo</em> models. Blood. 2012;120(21):2756.Google Scholar
  89. 89.
    Le Garff-Tavernier M, et al. Analysis of CD16+CD56dim NK cells from CLL patients: evidence supporting a therapeutic strategy with optimized anti-CD20 monoclonal antibodies. Leukemia. 2011;25(1):101–9.PubMedGoogle Scholar
  90. 90.
    Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017;177(2):243–53.PubMedPubMedCentralGoogle Scholar
  91. 91.
    Cazin B, et al. Multicentre phase I study with an 8-dose regimen of single agent anti-CD20 monoclonal antibody LFB-R603 in patients with relapsed chronic lymphocytic leukemia (CLL). Blood. 2011;118(21):2862.Google Scholar
  92. 92.
    Nastoupil LJ, et al. Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL. J Clin Oncol. 2017;35(15_suppl):7511.Google Scholar
  93. 93.
    Prasad V, De Jesus K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14(6):381–90.PubMedGoogle Scholar
  94. 94.
    S, G. Remarks from FDA Commissioner Scott Gottlieb, M.D., as prepared for delivery at the Brookings Institution on the release of the FDA’s Biosimilars Action Plan. 2018; Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm613881.htm.
  95. 95.
    The Lancet H. Biosimilars: an optimistic outlook, but vigilance is needed. Lancet Haematol. 2017;4(8):e341.Google Scholar
  96. 96.
    Rioufol C, Salles G. Biosimilar monoclonal antibodies in lymphoma: a critical appraisal. Expert Rev Anticancer Ther. 2015;15(5):569–78.PubMedGoogle Scholar
  97. 97.
    Biosimilars in the EU - information guide for healthcare professionals. 2017 [cited 2018 2 SEPT]; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf.
  98. 98.
    •• Vital EM, Kay J, Emery P. Rituximab biosimilars. Expert Opin Biol Ther. 2013;13(7):1049–62. Clear and comprehensive review of the manufacture, regulatory considerations, and overall development of rituximab biosimilars. PubMedGoogle Scholar
  99. 99.
    Schiestl M, Stangler T, Torella C, Čepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol. 2011;29:310–2.PubMedGoogle Scholar
  100. 100.
    Jurczak W, Moreira I, Kanakasetty GB, Munhoz E, Echeveste MA, Giri P, et al. Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study. Lancet Haematol. 2017;4(8):e350–61.PubMedGoogle Scholar
  101. 101.
    Association E.M. Summary of product characteristics: rixathon 2018; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003903/WC500232460.pdf.
  102. 102.
    Association E.M. Summary of product characteristics: truxima 2018; Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/004112/WC500222694.pdf.
  103. 103.
    Qureshi ZP, et al. Rituximab and biosimilars – equivalence and reciprocity. Biosimilars. 2013;2013(3):19–25.PubMedPubMedCentralGoogle Scholar
  104. 104.
    Viswabandya A, et al. Pharmacokinetic and pharmacodynamic evaluation of a biosimilar rituximab in newly diagnosed diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, adriamycin, vincristine, prednisolone). Blood. 2007;110(11):4491.Google Scholar
  105. 105.
    Roy PS, et al. Comparison of the efficacy and safety of rituximab (Mabthera) and its biosimilar (Reditux) in diffuse large B-cell lymphoma patients treated with chemo-immunotherapy: a retrospective analysis. Indian J Med Paediatr Oncol. 2013;34(4):292–8.PubMedPubMedCentralGoogle Scholar
  106. 106.
    Gota V, Karanam A, Rath S, Yadav A, Tembhare P, Subramanian P, et al. Population pharmacokinetics of Reditux, a biosimilar rituximab, in diffuse large B-cell lymphoma. Cancer Chemother Pharmacol. 2016;78(2):353–9.PubMedGoogle Scholar
  107. 107.
    Menon H, et al. Pharmacokinetic and pharmacodynamic properties of a biosimilar rituximab (Reditux<sup>®</sup>) are identical to the innovator brand MabThera<sup>®</sup>− experience from a tertiary cancer centre in Western India. Blood. 2014;124(21):2246.Google Scholar
  108. 108.
    Gulácsi L, Brodszky V, Baji P, Rencz F, Péntek M. The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries. Adv Ther. 2017;34(5):1128–44.PubMedPubMedCentralGoogle Scholar
  109. 109.
    Organization, W.H. WHO model list of essential medicines: 20th edition. 2017 [cited 2018 2 sept]; Available from: http://apps.who.int/iris/bitstream/handle/10665/273826/EML-20-eng.pdf?ua=1.
  110. 110.
    Chopra R, Lopes G. Improving access to cancer treatments: the role of biosimilars. J Global Oncol. 2017;3(5):596–610.Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.BC CancerVancouverCanada

Personalised recommendations